Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Niamh Keane, MB, MRCP, Caleb K Stein, MS, Daniel Angelov, MSc,MB, Shulan Tian, David Viswanatha, MD, Shaji K Kumar, MD, Angela Dispenzieri, MD, Veronica Gonzalez De La Calle, MD, Kristine Misund, PhD, Robert A Kyle, MD, Michael E O'Dwyer, MD, Rafael Fonseca, MD, A. Keith Stewart, MBChB, MBA, Esteban Braggio, PhD, Yan Asmann, PhD, S. Vincent Rajkumar, MD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 393.

https://doi.org/10.1182/blood.V130.Suppl_1.393.393

Published: 2017

Journal Articles

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Meaghen E Sharik, BS, Caleb K Stein, MS, Gregory J Ahmann, BS, Ilsel D Lopez Armenta, BS, Nikolai Sepetov, PhD, Sergei Romanov, PhD, P. Leif Bergsagel, MD, Marta Chesi, PhD, Nathalie Meurice, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 4423.

https://doi.org/10.1182/blood.V130.Suppl_1.4423.4423

Published: 2017

Journal Articles

Identifying High-Risk Phenotypes Using Three-Way Feature Interactions in Multiple Myeloma: An Analysis of Publically Available Mmrf Commpass Study

Caleb K Stein, MS, Yan Asmann, PhD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 3034.

https://doi.org/10.1182/blood.V130.Suppl_1.3034.3034

Published: 2017

Journal Articles

Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)

Paola Neri, MD, Ines Tagoug, PhD, Ranjan Maity, PhD, Caleb K Stein, MS, Madison Kong, Jonathan Keats, PhD, David Soong, PhD, Christopher Chiu, PhD, P. Leif Bergsagel, MD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 63.

https://doi.org/10.1182/blood.V130.Suppl_1.63.63

Published: 2017

Journal Articles

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Blood (2016) 128 (22): 117.

https://doi.org/10.1182/blood.V128.22.117.117

Published: 2016

Journal Articles

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Blood (2016) 128 (22): 3278.

https://doi.org/10.1182/blood.V128.22.3278.3278

Published: 2016

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Charlotte Pawlyn, MB BChir, Michael Bright, PhD, Amy Buros, PhD, Caleb K. Stein, MS, Zoe Walters, PhD, Lauren Aronson, PhD, Fabio Mirabella, PhD, Martin F Kaiser, MD, John R Jones, MD, Brian A Walker, PhD, Graham H Jackson, MD PhD, Paul Clarke, PhD, Leif Bergsagel, MD, Paul Workman, PhD, Marta Chesi, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3289.

https://doi.org/10.1182/blood.V128.22.3289.3289

Published: 2016

Journal Articles

The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma

Brian A Walker, PhD, Mehmet K. Samur, PhD, Konstantinos Mavrommatis, Cody Ashby, PhD, Christopher P Wardell, PhD, Maria Ortiz, PhD, Fadi Towfic, Caleb K. Stein, MS, Michael A Bauer, PhD, Michael Amatangelo, PhD, Giovanni Parmigiani, PhD, Zhinuan Yu, PhD, Matthew Trotter, Herve Avet-Loiseau, MD PhD, Graham H Jackson, MD PhD, Kenneth C. Anderson, Anjan Thakurta, PhD, Nikhil C. Munshi, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 196.

https://doi.org/10.1182/blood.V128.22.196.196

Published: 2016

Journal Articles

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

Blood (2016) 128 (22): 4416.

https://doi.org/10.1182/blood.V128.22.4416.4416

Published: 2016

Journal Articles

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

Leo Rasche, MD, Amy Buros, PhD, Niels Weinhold, PhD, Caleb K. Stein, MS, James E McDonald, Shweta S. Chavan, PhD, Edgardo Angtuaco, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 4431.

https://doi.org/10.1182/blood.V128.22.4431.4431

Published: 2016

Journal Articles

The Mutational and Signaling Landscape of Multiple Myeloma Varies Dependent upon Translocation Cyclin D (TC) Subgroup

Caleb K. Stein, MS, Charlotte Pawlyn, MB BChir, Shweta S. Chavan, PhD, Niels Weinhold, PhD, Brian A Walker, PhD, Adam Rosenthal, Ola Landgren, MD, PhD, Peter Leif Bergsagel, MD PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 4441.

https://doi.org/10.1182/blood.V128.22.4441.4441

Published: 2016

Journal Articles

47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma

Xenofon Papanikolaou, MD, Caleb K. Stein, MS, Ricky D Edmondson, PhD, Veronica Macleod, Ruslana Tytarenko, Bart Barlogie, MD PhD, Joshua Epstein, DSc, Christoph Heuck, MD

Blood (2015) 126 (23): 499.

https://doi.org/10.1182/blood.V126.23.499.499

Published: 2015

Journal Articles

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

Blood (2015) 126 (23): 369.

https://doi.org/10.1182/blood.V126.23.369.369

Published: 2015

Journal Articles

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Blood (2015) 126 (23): 372.

https://doi.org/10.1182/blood.V126.23.372.372

Published: 2015

Journal Articles

Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials

Sharmilan Thanendrarajan, MD, Caleb K. Stein, MS, Faith E Davies, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Carolina Schinke, MD, Sarah Waheed, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Niels Weinhold, PhD, Aasiya Matin, Pankaj Mathur, Meera Mohan, Muthukumar Radhakrishnan, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 3182.

https://doi.org/10.1182/blood.V126.23.3182.3182

Published: 2015

Journal Articles

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Caleb K. Stein, MS, Faith E Davies, MD, Christoph Heuck, MD, Niels Weinhold, PhD, Shweta S. Chavan, PhD, Brian A Walker, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Martin F Kaiser, MD, Graham H Jackson, MD PhD, Pieter Sonneveld, MD PhD, Hartmut Goldschmidt, MD, Peter Leif Bergsagel, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 4173.

https://doi.org/10.1182/blood.V126.23.4173.4173

Published: 2015

Journal Articles

Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy

Priyangi A Malaviarachchi, BS, Donald E Turner, BS, Caleb K. Stein, MS, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Sarah K. Johnson, PhD

Blood (2015) 126 (23): 1820.

https://doi.org/10.1182/blood.V126.23.1820.1820

Published: 2015

Journal Articles

Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines

Charlotte Pawlyn, MB BChir, Tim Chambers, Veronica Macleod, Daniel Sappington, Amy Buros, PhD, Caleb K. Stein, MS, Martin F Kaiser, MD, Rosemary Burke, Swen Hoelder, Gunnar Boysen, Ricky D Edmondson, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2015) 126 (23): 1792.

https://doi.org/10.1182/blood.V126.23.1792.1792

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Blood (2015) 126 (23): 20.

https://doi.org/10.1182/blood.V126.23.20.20

Published: 2015

NARROW

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Identifying High-Risk Phenotypes Using Three-Way Feature Interactions in Multiple Myeloma: An Analysis of Publically Available Mmrf Commpass Study

Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

The Mutational and Signaling Landscape of Multiple Myeloma Varies Dependent upon Translocation Cyclin D (TC) Subgroup

47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy

Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only